Important Safety Information | NIOX VERO® User Manual (PDF)

For Healthcare Professionals Only

EN

Distributors

The device of choice for clinical research1


NIOX® is trusted by sponsors, CROs and researchers across the globe and has been used in over 6,000 studies, including pivotal clinical trials for new asthma biologics.1


GET STARTED
A NIOX VERO® FeNO testing device

NIOX®, the world leader in FeNO

As the pioneers of commercial FeNO testing, NIOX® Technology is trusted wordwide1,2 supporting FeNO testing in clinical trials through thought-leadership, insights, and expertise. NIOX® is here to support you with your research. Our dedicated global teams are ready to ensure that you get the very best from NIOX®.

Dedicated support from our experts

NIOX® is the device of choice for clinical research, with over 25 years of innovation, and trusted by thousands of healthcare professionals worldwide.1,2 NIOX® Technology is classed as the gold standard for FeNO testing.1 See below to find out how we support you with your research.

Partnership Model

By choosing NIOX® you will be connected to a dedicated account manager who will be on hand for all your NIOX® needs.


Advanced technical
support

With NIOX® you will unlock exclusive training and technical support to assist you with your research, meaning you can not only connect your sites together, but be assured someone is here to help if you ever need advice for your devices.


Sustainability for the
future

Sustainability is a key factor in the heart of what we do at NIOX®. We help you get the full value out of each and every device through our reverification and anonymization services, allowing one device to be repurposed for multiple studies whilst limiting waste.


International logistical
provisions

Our global distribution network ensures door-to-door tracking. Whether you want your devices shipped directly to site or in bulk to depots, NIOX® distribution can accommodate your requirements worldwide.


Connectivity capabilities

Introducing a new way to interact with NIOX® with NIOX® Panel Apps. The connectivity options for the gold standard NIOX VERO® allow you to connect your sites globally, enhancing your FeNO for research experience.1

ABOUT NIOX® APPS

A doctor and patient performing a FeNO test with NIOX VERO®

FeNO – the biomarker supporting research

FeNO provides an objective measure of Type 2 airway inflammation, with its use in research including treatments targeting IL-4 and IL-13.3-6 FeNO has been used in clinical research and trials for over a decade.7-11 FeNO can help determine patient inclusion/exclusion criteria, monitor airway inflammation and medication adherence, optimize dosage, and guide biologic treatments.4,12,13

The only FeNO testing device in the USA and EU market that fully conforms to ATS/ERS standards1,8

The gold standard in FeNO testing

The NIOX VERO® is the device of choice for FeNO testing and used by thousands of healthcare professionals across the globe.1,2 The device is packed with distinctive and dependable technology to ensure that results are accurate and reliable each and every time.1,3,14-16

WHY NIOX® ABOUT NIOX VERO®

Get started with NIOX VERO®

Join the thousands of healthcare professionals who have already performed over 50 million FeNO tests with NIOX VERO®. Use our contact form below or get in touch with us via email: global.research@niox.com.

References

1. NIOX® Data on File; MKT-DOF-007. 2023.
2. NIOX® Data on File; MKT-DOF-013. 2024.
3. Alving K et al. Validation of a new portable exhaled nitric oxide analyzer, NIOX VERO®: randomized studies in asthma. Pulm Ther. 2017;3:207-218.
4. Hanania NA et al. Measurement of fractional exhaled nitric oxide in real-world clinical practice alters asthma treatment decisions. Ann Allergy Asthma Immunol. 2018;120(4):414-418.
5. Busse W et al. Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis. The Lancet Respiratory Medicine. 2021;9(10):1165-73.
6. Pianigiani T et al. Exploring the interaction between fractional exhaled nitric oxide and biologic treatment in severe asthma: A systematic review. Antioxidants. 2023;12(2):400.
7. Dweik RA et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FeNO) for clinical applications. Am J Respir Crit Care Med. 2011;184(5):602-15.
8. American Thoracic Society; European Respiratory Society. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med. 2005;171(8):912-30.
9. Buchvald F et al. Measurements of exhaled nitric oxide in healthy subjects age 4 to 17 years. Journal of Allergy and Clinical Immunology. 2005;115(6):1130-6.
10. Kharitonov S et al. Reproducibility of exhaled nitric oxide measurements in healthy and asthmatic adults and children. European Respiratory Journal. 2003;21(3):433-8.
11. Smith AD et al. Exhaled nitric oxide: a predictor of steroid response. Am J Respir Crit Care Med. 2005;172(4):453-9.
12. Heaney LG et al. Medical Research Council UK Refractory Asthma Stratification Programme (RASP-UK). Remotely monitored therapy and nitric oxide suppression identifies nonadherence in severe asthma. Am J Respir Crit Care Med. 2019;199(4):454-464.
13. Loewenthal L et al. FeNO in asthma. Semin Respir Crit Care Med. 2022;43:635-645.
14. Heffler E et al. Fractional Exhaled Nitric Oxide (FENO) in the management of asthma: a position paper of the Italian Respiratory Society (SIP/IRS) and Italian Society of Allergy, Asthma and Clinical Immunology (SIAAIC). Multidisciplinary respiratory medicine. 2020;15(1).
15. Gao J et al. Association between fractional exhaled nitric oxide, sputum induction and peripheral blood eosinophil in uncontrolled asthma. Allergy, Asthma & Clinical Immunology. 2018;1.
16. Carroll WD. NIOX VERO: Individualized Asthma Management in Clinical Practice. Pulmonary Therapy. 2016;2:171-88.